A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine
Authors:
- 1 October 1994
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 350 (4) , 434-439
Abstract
The sparteine/debrisoquine polymorphism is a clinically important genetic deficiency of cytochrome P4502136-catalyzed oxidative drug metabolism. 5–10% of Caucasians designated as poor metabolizers have a severely impaired capacity to metabolize more than 30 therapeutically used drugs. Genotyping of a random Caucasian population for the known cytochrome P4502D6 mutations A, B and D which are associated with the poor metabolizer phenotype has revealed a substantial number of misclassified poor metabolizers indicating the existence of one or more unknown mutations which cannot be identified with the currently available genotyping assays. Therefore we have cloned and sequenced one nonfunctional cytochrome P4502D6 allele of a. misclassified poor metabolizer and could identify a single missense mutation designated E mutation at position 3023(A–C) in exon 6. Direct sequencing analysis, Fokl restriction analysis and a newly developed allele-specific polymerase chain reaction assay were applied to analyze for this mutation in a population study. Three out of 97 randomly selected Caucasians were carriers of this mutation and thus the E allele has a frequency of 1.5% (confidence interval95% = 0.33–4.54%). Since only 2 out of 4 misclassified poor metabolizers carried the E mutation, additional unknown mutant alleles must exist. Computer modelling suggests that the E mutation, which results in a histidine to proline exchange in position 324 of the protein, may cause an alteration of the 3D structure of CYP2D6 in close vicinity to the active site thereby leading to total loss of enzyme function.Keywords
This publication has 23 references indexed in Scilit:
- The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probesPharmacogenetics, 1994
- Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.1993
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypePharmacogenetics, 1991
- THE HUMAN CYP2D LOCUS ASSOCIATED WITH A COMMON GENETIC-DEFECT IN DRUG OXIDATION - A G1934-]A BASE CHANGE IN INTRON-3 OF A MUTANT CYP2D6 ALLELE RESULTS IN AN ABERRANT-3' SPLICE RECOGNITION SITE1990
- Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populationsEuropean Journal of Clinical Pharmacology, 1990
- Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplificationThe Lancet, 1990
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entitiesClinical Pharmacology & Therapeutics, 1982
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteinsJournal of Molecular Biology, 1978